206 related articles for article (PubMed ID: 30556932)
21. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
22. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
23. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
25. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
[TBL] [Abstract][Full Text] [Related]
26. Distinguishing Progression from Pseudoprogression in Glioblastoma Using
Nabavizadeh A; Bagley SJ; Doot RK; Ware JB; Young AJ; Ghodasara S; Zhao C; Anderson H; Schubert E; Carpenter EL; Till J; Henderson F; Pantel AR; Chen HI; Lee JYK; Amankulor NM; O'Rourke DM; Desai A; Nasrallah MP; Brem S
J Nucl Med; 2023 Jun; 64(6):852-858. PubMed ID: 36549916
[TBL] [Abstract][Full Text] [Related]
27. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis.
Wang Q; Zhang H; Zhang J; Wu C; Zhu W; Li F; Chen X; Xu B
Eur Radiol; 2016 Aug; 26(8):2670-84. PubMed ID: 26471274
[TBL] [Abstract][Full Text] [Related]
29. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.
Smith EA; Carlos RC; Junck LR; Tsien CI; Elias A; Sundgren PC
AJR Am J Roentgenol; 2009 Feb; 192(2):W45-52. PubMed ID: 19155380
[TBL] [Abstract][Full Text] [Related]
30. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury.
Zeng QS; Li CF; Zhang K; Liu H; Kang XS; Zhen JH
J Neurooncol; 2007 Aug; 84(1):63-9. PubMed ID: 17619225
[TBL] [Abstract][Full Text] [Related]
31. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
32. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
33. 3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain.
Pelletier D; Nelson SJ; Grenier D; Lu Y; Genain C; Goodkin DE
Magn Reson Imaging; 2002 Oct; 20(8):599-606. PubMed ID: 12467867
[TBL] [Abstract][Full Text] [Related]
34. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps.
Reimer C; Deike K; Graf M; Reimer P; Wiestler B; Floca RO; Kickingereder P; Schlemmer HP; Wick W; Bendszus M; Radbruch A
PLoS One; 2017; 12(4):e0174620. PubMed ID: 28384170
[TBL] [Abstract][Full Text] [Related]
36. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
[TBL] [Abstract][Full Text] [Related]
37. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
38. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
[TBL] [Abstract][Full Text] [Related]
39. Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Perry LA; Korfiatis P; Agrawal JP; Erickson BJ
Neuroradiology; 2018 Jan; 60(1):35-42. PubMed ID: 29103145
[TBL] [Abstract][Full Text] [Related]
40. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
Kim H; Catana C; Ratai EM; Andronesi OC; Jennings DL; Batchelor TT; Jain RK; Sorensen AG
Cancer Res; 2011 Jun; 71(11):3745-52. PubMed ID: 21507932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
